MedTrace Logo

Advance Care Planning: A Way to Improve End-of-life Care Life Care

NCT01944813 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2014-12-23

No results posted yet for this study

Summary

Communication about end-of-life issues is often suboptimal. A way to improve the quality of end-of-life care is Advance Care Planning (ACP). ACP is a discussion between an incurable ill patient and the health professionals about preferences for end-of-life care. In Denmark, there is no tradition of systematic communication with patients about end-of-life care. The aim is to investigate how ACP can be beneficial among incurable ill patients treated in an outpatient context and if the concept is feasible in a Danish context. The study is designed as a prospective randomised controlled trial. Patients from relevant departments will be included and randomised in two groups: one receiving usual care and the other receiving usual care and ACP. Data will be collected from Electronic Patient Files and from questionnaires. If ACP is effective, it will improve the quality of end-of-life care for patients and their families and reduce the psychological distress in the bereaved relatives.

Conditions

Interventions

BEHAVIORAL

ACp conversation

Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.

Sponsors & Collaborators

  • TrygFonden, Denmark

    collaborator INDUSTRY

  • Danish Cancer Society

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Anders B Jensen, Professor · Department of oncology Aarhus University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944813 on ClinicalTrials.gov